Linked Life Data

17925892

Source:http://linkedlifedata.com/resource/pubmed/id/17925892

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2007-10-10
pubmed:abstractText
Alzheimer's disease is the most common cause of dementia characterized by progressive neurodegeneration. Recently, a vaccine therapy for Alzheimer's disease was developed as a curative treatment. Although clinical trials of active vaccination for Alzheimer's disease were halted due to the development of meningoencephalitis in some patients, the clinical and pathological findings of treated patients suggest that the vaccine therapy is effective. Hence, newly designed vaccines are being invented to control excessive T-cell immune reactions after the human clinical trial. In this article, we will review conventional vaccine therapies and newly developed vaccine therapies, mainly DNA vaccines, for possible clinical application in the near future.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0214-0934
pubmed:author
pubmed:copyrightInfo
(c) 2007 Prous Science. All rights reserved.
pubmed:issnType
Print
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
379-86
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:articleTitle
Development of anti-Abeta vaccination as a promising therapy for Alzheimer's disease.
pubmed:affiliation
Department of Molecular Neuropathology, Tokyo Metropolitan Institute for Neuroscience, Tokyo, Japan.
pubmed:publicationType
Journal Article, Review